Anna Bobrus-Chociej (Anna Bobrus-Chcociej)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Insulin Resistance

Body Mass Index

Top Venues

Medical science monitor : international medical journal of experimental and clinical research

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Kinga Półkośnik, Marta Flisiak-Jackiewicz, Anna Bobrus-Chociej, Anna Lebensztejn, Małgorzata Wojtkowska, Jacek Jamiolkowski, Dariusz Marek Lebensztejn
Biochemical and Anthropometric Indices of Insulin Resistance in Obese and Overweight Children with Metabolic Dysfunction-Associated Fatty Liver Disease. Medical science monitor : international medical journal of experimental and clinical research 30 (2024)
Kinga Półkośnik, Marta Flisiak-Jackiewicz, Anna Bobrus-Chociej, Anna Lebensztejn, Małgorzata Wojtkowska, Jacek Jamiolkowski, Dariusz Marek Lebensztejn
Biochemical and Anthropometric Indices of Insulin Resistance in Obese and Overweight Children with Metabolic Dysfunction-Associated Fatty Liver Disease. Medical science monitor : international medical journal of experimental and clinical research 30 (2024)
Kinga Półkośnik, Marta Flisiak-Jackiewicz, Anna Bobrus-Chociej, Anna Lebensztejn, Małgorzata Wojtkowska, Jacek Jamiolkowski, Dariusz Marek Lebensztejn
Biochemical and Anthropometric Indices of Insulin Resistance in Obese and Overweight Children with Metabolic Dysfunction-Associated Fatty Liver Disease. Medical science monitor : international medical journal of experimental and clinical research 30 (2024)
Katarzyna Zdanowicz, Anna Bobrus-Chociej, Karolina Pogodzinska, Agnieszka Urszula Błachnio-Zabielska, Beata Zelazowska-Rutkowska, Dariusz Marek Lebensztejn, Urszula Daniluk
Analysis of Sphingolipids in Pediatric Patients with Cholelithiasis-A Preliminary Study. Journal of clinical medicine 11 (19) (2022)
Katarzyna Zdanowicz, Anna Bobrus-Chociej, Dariusz Marek Lebensztejn
Chemerin as Potential Biomarker in Pediatric Diseases: A PRISMA-Compliant Study. Biomedicines 10 (3) (2022)